Respiratory system involvement in brucellosis: the results of the Kardelen study

Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis. This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respirat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chest 2014-01, Vol.145 (1), p.87-94
Hauptverfasser: Erdem, Hakan, Inan, Asuman, Elaldi, Nazif, Tekin, Recep, Gulsun, Serda, Ataman-Hatipoglu, Cigdem, Beeching, Nicholas, Deveci, Özcan, Yalci, Aysun, Bolukcu, Sibel, Dagli, Ozgur
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 94
container_issue 1
container_start_page 87
container_title Chest
container_volume 145
creator Erdem, Hakan
Inan, Asuman
Elaldi, Nazif
Tekin, Recep
Gulsun, Serda
Ataman-Hatipoglu, Cigdem
Beeching, Nicholas
Deveci, Özcan
Yalci, Aysun
Bolukcu, Sibel
Dagli, Ozgur
description Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis. This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respiratory system involvement. Of 133 patients (67 men), 123 (92.5%) had acute infection (defined as < 2 months), with an overall mean ± SD duration of symptoms of 33.9 ± 8.5 days. The radiologic pattern of pulmonary disease was consolidation/lobar pneumonia in 91 patients (68.4%) and pleural effusion in 41 patients (30.8%), including 30 (22.5%) with both. Moreover, 23 patients (17.3%) had bronchitis (one with coexistent pneumonia), and 10 (7.5%) had nodular lung lesions (one with coexistent pneumonia and effusion). Blood culture results were positive in 56 of 119 patients, and all other cases were serologically confirmed. None of 60 sputum specimens and two of 19 pleural fluid samples (10.5%) yielded positive culture results for brucellosis. Other features of brucellosis, such as osteoarticular complications, were detected in 61 patients (45.9%); 59 (44.4%) had raised liver transaminase levels, and 59 (44.4%) had thrombocytopenia. Fifteen patients (11.3%) required management in an ICU for an average of 3.8 ± 2.2 days. All patients responded to standard combination antimicrobial therapy for brucellosis with no deaths, although treatment regimens required modification in seven patients. Brucellosis with pulmonary involvement is rare but has a good prognosis following treatment with appropriate antibiotics. Many clues in the exposure history, presenting clinical features, and baseline blood tests should alert the clinician to consider brucellosis.
doi_str_mv 10.1378/chest.13-0240
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490703671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490703671</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-b217882f2e843096b6e9032a707fecae989db752c6f6e1c32b5928853be2a9503</originalsourceid><addsrcrecordid>eNo1UEtLxDAYDIK46-rRq-TopZpH2yTeZHFVXFBEzyVpv7KVvsyXLPTfW3U9zQwMw8wQcsHZNZdK35Q7wDDThImUHZElN5InMkvlgpwifjLGODf5CVkIaZiSSizJ6xvg2HgbBj9RnDBAR5t-P7R76KAPM6fOxxLadsAGb2nYAfWAsQ1Ih_pXPltfQQs9xRCr6Ywc17ZFOD_ginxs7t_Xj8n25eFpfbdNRsF5SJzgSmtRC9CpZCZ3ORgmhVVM1VBaMNpUTmWizOsceCmFy4zQOpMOhDUZkyty9Zc7-uErzruLrsGfnraHIWLB03kik7nis_XyYI2ug6oYfdNZPxX_L8hvYStdaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490703671</pqid></control><display><type>article</type><title>Respiratory system involvement in brucellosis: the results of the Kardelen study</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Erdem, Hakan ; Inan, Asuman ; Elaldi, Nazif ; Tekin, Recep ; Gulsun, Serda ; Ataman-Hatipoglu, Cigdem ; Beeching, Nicholas ; Deveci, Özcan ; Yalci, Aysun ; Bolukcu, Sibel ; Dagli, Ozgur</creator><creatorcontrib>Erdem, Hakan ; Inan, Asuman ; Elaldi, Nazif ; Tekin, Recep ; Gulsun, Serda ; Ataman-Hatipoglu, Cigdem ; Beeching, Nicholas ; Deveci, Özcan ; Yalci, Aysun ; Bolukcu, Sibel ; Dagli, Ozgur ; Brucellosis Study Group</creatorcontrib><description>Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis. This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respiratory system involvement. Of 133 patients (67 men), 123 (92.5%) had acute infection (defined as &lt; 2 months), with an overall mean ± SD duration of symptoms of 33.9 ± 8.5 days. The radiologic pattern of pulmonary disease was consolidation/lobar pneumonia in 91 patients (68.4%) and pleural effusion in 41 patients (30.8%), including 30 (22.5%) with both. Moreover, 23 patients (17.3%) had bronchitis (one with coexistent pneumonia), and 10 (7.5%) had nodular lung lesions (one with coexistent pneumonia and effusion). Blood culture results were positive in 56 of 119 patients, and all other cases were serologically confirmed. None of 60 sputum specimens and two of 19 pleural fluid samples (10.5%) yielded positive culture results for brucellosis. Other features of brucellosis, such as osteoarticular complications, were detected in 61 patients (45.9%); 59 (44.4%) had raised liver transaminase levels, and 59 (44.4%) had thrombocytopenia. Fifteen patients (11.3%) required management in an ICU for an average of 3.8 ± 2.2 days. All patients responded to standard combination antimicrobial therapy for brucellosis with no deaths, although treatment regimens required modification in seven patients. Brucellosis with pulmonary involvement is rare but has a good prognosis following treatment with appropriate antibiotics. Many clues in the exposure history, presenting clinical features, and baseline blood tests should alert the clinician to consider brucellosis.</description><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.13-0240</identifier><identifier>PMID: 23907372</identifier><language>eng</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Bronchitis - diagnosis ; Bronchitis - drug therapy ; Brucellosis - diagnosis ; Brucellosis - drug therapy ; Ceftriaxone ; Doxycycline - therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Pleural Effusion - diagnosis ; Pleural Effusion - drug therapy ; Pneumonia - diagnosis ; Pneumonia - drug therapy ; Prognosis ; Retrospective Studies ; Rifampin - therapeutic use ; Streptomycin - therapeutic use ; Turkey ; Young Adult</subject><ispartof>Chest, 2014-01, Vol.145 (1), p.87-94</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23907372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Erdem, Hakan</creatorcontrib><creatorcontrib>Inan, Asuman</creatorcontrib><creatorcontrib>Elaldi, Nazif</creatorcontrib><creatorcontrib>Tekin, Recep</creatorcontrib><creatorcontrib>Gulsun, Serda</creatorcontrib><creatorcontrib>Ataman-Hatipoglu, Cigdem</creatorcontrib><creatorcontrib>Beeching, Nicholas</creatorcontrib><creatorcontrib>Deveci, Özcan</creatorcontrib><creatorcontrib>Yalci, Aysun</creatorcontrib><creatorcontrib>Bolukcu, Sibel</creatorcontrib><creatorcontrib>Dagli, Ozgur</creatorcontrib><creatorcontrib>Brucellosis Study Group</creatorcontrib><title>Respiratory system involvement in brucellosis: the results of the Kardelen study</title><title>Chest</title><addtitle>Chest</addtitle><description>Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis. This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respiratory system involvement. Of 133 patients (67 men), 123 (92.5%) had acute infection (defined as &lt; 2 months), with an overall mean ± SD duration of symptoms of 33.9 ± 8.5 days. The radiologic pattern of pulmonary disease was consolidation/lobar pneumonia in 91 patients (68.4%) and pleural effusion in 41 patients (30.8%), including 30 (22.5%) with both. Moreover, 23 patients (17.3%) had bronchitis (one with coexistent pneumonia), and 10 (7.5%) had nodular lung lesions (one with coexistent pneumonia and effusion). Blood culture results were positive in 56 of 119 patients, and all other cases were serologically confirmed. None of 60 sputum specimens and two of 19 pleural fluid samples (10.5%) yielded positive culture results for brucellosis. Other features of brucellosis, such as osteoarticular complications, were detected in 61 patients (45.9%); 59 (44.4%) had raised liver transaminase levels, and 59 (44.4%) had thrombocytopenia. Fifteen patients (11.3%) required management in an ICU for an average of 3.8 ± 2.2 days. All patients responded to standard combination antimicrobial therapy for brucellosis with no deaths, although treatment regimens required modification in seven patients. Brucellosis with pulmonary involvement is rare but has a good prognosis following treatment with appropriate antibiotics. Many clues in the exposure history, presenting clinical features, and baseline blood tests should alert the clinician to consider brucellosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bronchitis - diagnosis</subject><subject>Bronchitis - drug therapy</subject><subject>Brucellosis - diagnosis</subject><subject>Brucellosis - drug therapy</subject><subject>Ceftriaxone</subject><subject>Doxycycline - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pleural Effusion - diagnosis</subject><subject>Pleural Effusion - drug therapy</subject><subject>Pneumonia - diagnosis</subject><subject>Pneumonia - drug therapy</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Rifampin - therapeutic use</subject><subject>Streptomycin - therapeutic use</subject><subject>Turkey</subject><subject>Young Adult</subject><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UEtLxDAYDIK46-rRq-TopZpH2yTeZHFVXFBEzyVpv7KVvsyXLPTfW3U9zQwMw8wQcsHZNZdK35Q7wDDThImUHZElN5InMkvlgpwifjLGODf5CVkIaZiSSizJ6xvg2HgbBj9RnDBAR5t-P7R76KAPM6fOxxLadsAGb2nYAfWAsQ1Ih_pXPltfQQs9xRCr6Ywc17ZFOD_ginxs7t_Xj8n25eFpfbdNRsF5SJzgSmtRC9CpZCZ3ORgmhVVM1VBaMNpUTmWizOsceCmFy4zQOpMOhDUZkyty9Zc7-uErzruLrsGfnraHIWLB03kik7nis_XyYI2ug6oYfdNZPxX_L8hvYStdaQ</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Erdem, Hakan</creator><creator>Inan, Asuman</creator><creator>Elaldi, Nazif</creator><creator>Tekin, Recep</creator><creator>Gulsun, Serda</creator><creator>Ataman-Hatipoglu, Cigdem</creator><creator>Beeching, Nicholas</creator><creator>Deveci, Özcan</creator><creator>Yalci, Aysun</creator><creator>Bolukcu, Sibel</creator><creator>Dagli, Ozgur</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201401</creationdate><title>Respiratory system involvement in brucellosis: the results of the Kardelen study</title><author>Erdem, Hakan ; Inan, Asuman ; Elaldi, Nazif ; Tekin, Recep ; Gulsun, Serda ; Ataman-Hatipoglu, Cigdem ; Beeching, Nicholas ; Deveci, Özcan ; Yalci, Aysun ; Bolukcu, Sibel ; Dagli, Ozgur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-b217882f2e843096b6e9032a707fecae989db752c6f6e1c32b5928853be2a9503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bronchitis - diagnosis</topic><topic>Bronchitis - drug therapy</topic><topic>Brucellosis - diagnosis</topic><topic>Brucellosis - drug therapy</topic><topic>Ceftriaxone</topic><topic>Doxycycline - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pleural Effusion - diagnosis</topic><topic>Pleural Effusion - drug therapy</topic><topic>Pneumonia - diagnosis</topic><topic>Pneumonia - drug therapy</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Rifampin - therapeutic use</topic><topic>Streptomycin - therapeutic use</topic><topic>Turkey</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erdem, Hakan</creatorcontrib><creatorcontrib>Inan, Asuman</creatorcontrib><creatorcontrib>Elaldi, Nazif</creatorcontrib><creatorcontrib>Tekin, Recep</creatorcontrib><creatorcontrib>Gulsun, Serda</creatorcontrib><creatorcontrib>Ataman-Hatipoglu, Cigdem</creatorcontrib><creatorcontrib>Beeching, Nicholas</creatorcontrib><creatorcontrib>Deveci, Özcan</creatorcontrib><creatorcontrib>Yalci, Aysun</creatorcontrib><creatorcontrib>Bolukcu, Sibel</creatorcontrib><creatorcontrib>Dagli, Ozgur</creatorcontrib><creatorcontrib>Brucellosis Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erdem, Hakan</au><au>Inan, Asuman</au><au>Elaldi, Nazif</au><au>Tekin, Recep</au><au>Gulsun, Serda</au><au>Ataman-Hatipoglu, Cigdem</au><au>Beeching, Nicholas</au><au>Deveci, Özcan</au><au>Yalci, Aysun</au><au>Bolukcu, Sibel</au><au>Dagli, Ozgur</au><aucorp>Brucellosis Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Respiratory system involvement in brucellosis: the results of the Kardelen study</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2014-01</date><risdate>2014</risdate><volume>145</volume><issue>1</issue><spage>87</spage><epage>94</epage><pages>87-94</pages><eissn>1931-3543</eissn><abstract>Pulmonary involvement is a rare complication of brucellosis. We describe the largest series to date, to our knowledge, of patients with pulmonary brucellosis. This 10-year, retrospective, descriptive study involved 27 centers in Turkey, including all patients with brucellosis with confirmed respiratory system involvement. Of 133 patients (67 men), 123 (92.5%) had acute infection (defined as &lt; 2 months), with an overall mean ± SD duration of symptoms of 33.9 ± 8.5 days. The radiologic pattern of pulmonary disease was consolidation/lobar pneumonia in 91 patients (68.4%) and pleural effusion in 41 patients (30.8%), including 30 (22.5%) with both. Moreover, 23 patients (17.3%) had bronchitis (one with coexistent pneumonia), and 10 (7.5%) had nodular lung lesions (one with coexistent pneumonia and effusion). Blood culture results were positive in 56 of 119 patients, and all other cases were serologically confirmed. None of 60 sputum specimens and two of 19 pleural fluid samples (10.5%) yielded positive culture results for brucellosis. Other features of brucellosis, such as osteoarticular complications, were detected in 61 patients (45.9%); 59 (44.4%) had raised liver transaminase levels, and 59 (44.4%) had thrombocytopenia. Fifteen patients (11.3%) required management in an ICU for an average of 3.8 ± 2.2 days. All patients responded to standard combination antimicrobial therapy for brucellosis with no deaths, although treatment regimens required modification in seven patients. Brucellosis with pulmonary involvement is rare but has a good prognosis following treatment with appropriate antibiotics. Many clues in the exposure history, presenting clinical features, and baseline blood tests should alert the clinician to consider brucellosis.</abstract><cop>United States</cop><pmid>23907372</pmid><doi>10.1378/chest.13-0240</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1931-3543
ispartof Chest, 2014-01, Vol.145 (1), p.87-94
issn 1931-3543
language eng
recordid cdi_proquest_miscellaneous_1490703671
source MEDLINE; Journals@Ovid Complete; Alma/SFX Local Collection
subjects Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Bronchitis - diagnosis
Bronchitis - drug therapy
Brucellosis - diagnosis
Brucellosis - drug therapy
Ceftriaxone
Doxycycline - therapeutic use
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Pleural Effusion - diagnosis
Pleural Effusion - drug therapy
Pneumonia - diagnosis
Pneumonia - drug therapy
Prognosis
Retrospective Studies
Rifampin - therapeutic use
Streptomycin - therapeutic use
Turkey
Young Adult
title Respiratory system involvement in brucellosis: the results of the Kardelen study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A02%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Respiratory%20system%20involvement%20in%20brucellosis:%20the%20results%20of%20the%20Kardelen%20study&rft.jtitle=Chest&rft.au=Erdem,%20Hakan&rft.aucorp=Brucellosis%20Study%20Group&rft.date=2014-01&rft.volume=145&rft.issue=1&rft.spage=87&rft.epage=94&rft.pages=87-94&rft.eissn=1931-3543&rft_id=info:doi/10.1378/chest.13-0240&rft_dat=%3Cproquest_pubme%3E1490703671%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490703671&rft_id=info:pmid/23907372&rfr_iscdi=true